Proprietary Platform EuMederis' EuPort is a proprietary non-peptide modification that elevates peptide bioavailability and duration of action, producing proprietary new chemical entities with improved drug-like properties that can be licensed or co-developed with larger players to accelerate preclinical-to-clinical programs.

Key Indication Focus Near-term opportunities exist in osteoporosis (PTH1-34 fragment modifications leading to Eu-232) and pain (Eu-178 with peripheral analgesia and reduced central liability) plus asthma assets, making these indications attractive for licensing or collaboration.

Clinical Pathway EuMederis is actively seeking commercialization partners and investors to move preclinical candidates into clinical trials, with potential deal structures including upfront licensing, milestone payments, and royalties as assets advance.

Competitive Differentiation EuPort-modified peptides show very low nanomolar potency, very prolonged efficacy, and favorable safety signals such as no hypercalcemia in osteoporosis models and peripheral analgesia without central side effects, offering a differentiated value proposition for partners.

Partnership Readiness As a small, preclinical-focused company with a defined asset portfolio, EuMederis is well positioned for partnerships with CROs, big pharma development teams, or investors to fund IND-enabling studies and early clinical programs.